Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + fexofenadine
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
"Arm 3 probes" refers to a specific combination of diagnostic probe substrates—rosuvastatin and fexofenadine—utilized in the third arm of a Phase 1 clinical trial (NCT03037931) sponsored by Celgene (a Bristol Myers Squibb company). This study was designed to evaluate the drug-drug interaction (DDI) potential of enasidenib (IDHIFA), an IDH2 inhibitor, in patients with IDH2-mutated acute myeloid leukemia (AML). In this context, rosuvastatin serves as a phenotypic probe for the Breast Cancer Resistance Protein (BCRP) and Organic Anion Transporting Polypeptides (OATP1B1 and OATP1B3), while fexofenadine serves as a probe for P-glycoprotein (P-gp). By measuring the pharmacokinetic changes of these substrates when co-administered with enasidenib at steady state, researchers can determine the inhibitory or inductive effects of enasidenib on these specific drug transporters.
- Other names
- arm 3 probesarm3 probesarm-3 probesrosuvastatin and fexofenadine
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)HRH1 (Histamine H1 Receptor)SLCO1B3 (Organic anion transporting polypeptide 1B3)
Beyond the preview
Go deeper on rosuvastatin + fexofenadine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + fexofenadine.